Molecular targeting for treatment of human T-lymphotropic virus type 1 infection - 09/12/18
, Baratali Mashkani a, c, ⁎ Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
| páginas | 9 |
| Iconografías | 6 |
| Vídeos | 0 |
| Otros | 0 |
Graphical abstract |
Highlights |
• | A limited number of HIV-1 reverse transcriptase inhibitors can limit viral replication in HTLV-1 infected cells. |
• | AZT/IFN-α combination therapy has induced a rapid and durable response in ATLL patients. |
• | No significant response was observed in the HTLV-1 carriers with raltegravir therapy. |
• | Ritonavir displayed some ex vivo activity through inhibition of NF-κB activity, rather HTLV-1 protease. |
• | Niclosamide induces degradation of the Tax protein in the proteasome. |
Abstract |
Human T-cell lymphotropic virus type 1 (HTLV-1) infection is linked to adult T-cell leukemia-lymphoma (ATLL) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and several other disorders. ATLL occurs in approximately 5% of the 15–20 million people infected by HTLV-1 in the world. In general, ATLL is resistant to chemotherapy, which underlines the need for new and effective therapeutic strategies. Previous studies highlighted the role of viral enzymes, responsible for viral replication, and regulatory proteins such as Tax and HBZ in the progression of HTLV-1-associated diseases. There are conflicting reports on the efficacy of current enzyme inhibitors, mainly developed against human immunodeficiency virus (HIV), for treatment of HTLV-1 infection. New treatment approaches including monoclonal antibodies show promising results and exert significant cytotoxic effects on ATLL cells. This manuscript reviews the recent developments in molecular targeting for treatment of HTLV-1 infection.
El texto completo de este artículo está disponible en PDF.Keywords : Human T-cell lymphotropic virus 1 (HTLV-1), Adult T-cell leukemia-lymphoma (ATLL), Antiviral therapy, Reverse transcriptase, Integrase, Protease
Esquema
Vol 109
P. 770-778 - janvier 2019 Regresar al número
Artículo precedente
- A non-invasive, multi-target approach to treat diabetic retinopathy
- Angeline Julius, Waheeta Hopper
- An overview of plant-based interventions to ameliorate arsenic toxicity
- Ann Susan, Kayalvizhi Rajendran, Kaviarasi Sathyasivam, Uma Maheswari Krishnan
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?